



Rasha 123

04/04/2025 14:43:18

Main Information

Primary registry identifying number

LBCTR2018090151

Protocol number

Rasha123

MOH registration number

20555/2018

Study registered at the country of origin

Yes

Study registered at the country of origin: Specify

Type of registration

Prospective

Type of registration: Justify

N/A

Date of registration in national regulatory agency

15/09/2018

Primary sponsor

Rasha

Primary sponsor: Country of origin

Lebanon

Date of registration in primary registry

22/04/2020

Date of registration in national regulatory agency

15/09/2018

Public title

Rasha 123

Acronym

RH

Scientific title

Rasha 123

Acronym

RH

Brief summary of the study: English

Great Job

Brief summary of the study: Arabic

السجل الوطني للأبحاث السريرية
الأول من نوعه

Health conditions/problem studied: Specify

Heart Failure

Interventions: Specify

New medication

Key inclusion and exclusion criteria: Inclusion criteria

all adults

Key inclusion and exclusion criteria: Gender

Both

Key inclusion and exclusion criteria: Specify gender

Key inclusion and exclusion criteria: Age minimum

18

Key inclusion and exclusion criteria: Age maximum

75



Key inclusion and exclusion criteria: Exclusion criteria

less than 18

Type of study

Observational

Type of intervention

Pharmaceutical

Type of intervention: Specify type

pharmaceutical with behavioral

Trial scope

Therapy

Trial scope: Specify scope

N/A

Study design: Allocation

Non-randomized controlled trial

Study design: Masking

N/A

Study design: Control

Uncontrolled

Study phase

1 to 2

Study design: Purpose

Treatment

Study design: Specify purpose

N/A

Study design: Assignment

Other

Study design: Specify assignment

single arm

IMP has market authorization

No

IMP has market authorization: Specify

USA

Name of IMP

In Love

Year of authorization

2014

Month of authorization

4

Type of IMP

Others

Pharmaceutical class

heart diseases

Therapeutic indication

to treat heart failure

Therapeutic benefit

increase ejection fraction

Study model

Case-Control

Study model: Explain model

OK

Study model: Specify model

N/A

Time perspective

Prospective

Time perspective: Explain time perspective

Time perspective: Specify perspective

N/A



OK

Target follow-up duration

30

Target follow-up duration: Unit

Months

Number of groups/cohorts

4

Biospecimen retention

Samples without DNA

Biospecimen description

DNA saliva samples

Target sample size

1000

Actual enrollment target size

1

Date of first enrollment: Type

Anticipated

Date of first enrollment: Date

20/10/2018

Date of study closure: Type

Anticipated

Date of study closure: Date

20/10/2020

Recruitment status

Complete

Recruitment status: Specify

Date of completion

24/04/2020

IPD sharing statement plan

No

IPD sharing statement description

I do not want to share

Additional data URL

later

Admin comments

Trial status

Approved



Secondary Identifying Numbers

Full name of issuing authority	Secondary identifying number
KSA	25325
NO one	55555

Sources of Monetary or Material Support

Name
King faisal hospital

Secondary Sponsors

Name
NA

Contact for Public/Scientific Queries

Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Rasha Hamra	Beirut	Iceland	0255.0000	rasha@gmail	MOH
Scientific	Marie Ok	Beirut	Lebanon	565540000 0	marie@yahoo	MOH
Public	N N	Beirut	Belize	5555	r@yahoo	MOH

Centers/Hospitals Involved in the Study

Center/Hospital name	Name of principles investigator	Principles investigator speciality	Ethical approval
AUB	RH	Oncologist	Approved
USJ	RH	Oncologist	NA



Ethics Review

Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
American University of Beirut Medical Center King faisal hospital	11/10/2018	RH	@gmail	565458
Makassed General Hospital	11/12/2019	RH	@yahoo	3336661

Countries of Recruitment

Name
Lebanon

Health Conditions or Problems Studied

Condition	Code	Keyword
heart failure	Heart failure (I50)	RF

Interventions

Intervention	Description	Keyword
pharmaceutical and behavioral	new medication with lifestyle changes	RH and forever
New treatment	New	RH

Primary Outcomes

Name	Time Points	Measure
increast EF	in 6 months	EF

Key Secondary Outcomes

Name	Time Points	Measure
I dont have	later	Ok



Trial Results

Summary results

Study results globally

Date of posting of results summaries

Date of first journal publication of results

Results URL link

Baseline characteristics

Participant flow

Adverse events

Outcome measures

URL to protocol files